Dynavax Deal Could Bolster AstraZeneca’s Respiratory Disease Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies hope to develop new type of drug for asthma and chronic obstructive pulmonary disease.
You may also be interested in...
Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program
$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.
Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program
$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.
Dynavax To Seek Experienced Vaccines Partner To Commercialize Heplisav
The company reports positive Phase III data for the hepatitis B vaccine showing 98.5% seroprotection after two doses.